MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/jaha.123.033410

Медицинская библиотека · Journal of the American Heart Association · 2024

Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction.

Carland Corinne, Zhao Lei, Salman Oday, Cohen Jordana B, Zamani Payman, Xiao Qing, Dongre Ashok, Wang Zhaoqing, Ebert Christina, Greenawalt Danielle, van Empel Vanessa, Richards A Mark, Doughty Robert N, Rietzschel Ernst, Javaheri Ali, Wang Yixin, Schafer Peter H, Hersey Sarah, Carayannopoulos Leonidas N, Seiffert Dietmar, Chang Ching-Pin, Gordon David A, Ramirez-Valle Francisco, Mann Douglas L, Cappola Thomas P, Chirinos Julio A

СтатьяПоддержка NIH: внешняя программаМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value of urinary proteomics. The objective of our study was to identify urinary proteins/peptides associated with death and heart failure admission in patients with heart failure with preserved ejection fraction.

METHODS AND

RESULTS

The study population included participants enrolled in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial). The relationship between urine protein levels and the risk of death or heart failure admission was assessed using Cox regression, in both nonadjusted analyses and adjusting for urine creatinine levels, and the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score. A total of 426 (12.4%) TOPCAT participants had urinary protein data and were included. There were 40 urinary proteins/peptides significantly associated with death or heart failure admission in nonadjusted analyses, 21 of which were also significant adjusted analyses. Top proteins in the adjusted analysis included ANGPTL2 (angiopoietin-like protein 2) (hazard ratio [HR], 0.5731 [95% CI, 0.47-0.7]; P=3.13E-05), AMY2A (α amylase 2A) (HR, 0.5496 [95% CI, 0.44-0.69]; P=0.0001), and DNASE1 (deoxyribonuclease-1) (HR, 0.5704 [95% CI, 0.46-0.71]; P=0.0002). Higher urinary levels of proteins involved in fibrosis (collagen VI α-1, collagen XV α-1), metabolism (pancreatic α-amylase 2A/B, mannosidase α class 1A member 1), and inflammation (heat shock protein family D member 1, inducible T cell costimulatory ligand) were associated with a lower risk of death or heart failure admission.

CONCLUSIONS

Our study identifies several novel associations between urinary proteins/peptides and outcomes in heart failure with preserved ejection fraction. Many of these associations are independent of clinical risk scores and may aid in risk stratification in this patient population.

Для цитирования: Carland Corinne, Zhao Lei, Salman Oday, Cohen Jordana B, Zamani Payman, Xiao Qing, Dongre Ashok, Wang Zhaoqing, Ebert Christina, Greenawalt Danielle, van Empel Vanessa, Richards A Mark, Doughty Robert N, Rietzschel Ernst, Javaheri Ali, Wang Yixin, Schafer Peter H, Hersey Sarah, Carayannopoulos Leonidas N, Seiffert Dietmar, Chang Ching-Pin, Gordon David A, Ramirez-Valle Francisco, Mann Douglas L, Cappola Thomas P, Chirinos Julio A. Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction.. Journal of the American Heart Association. 2024. DOI: 10.1161/jaha.123.033410.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.